Pfizer Inc.'s Zavicefta, which is used the treatment of Gram-negative bacterial infections requiring hospitalization, is available in Germany and the United Kingdom.
“The launch of Zavicefta reaffirms Pfizer’s longstanding heritage and commitment to patients facing serious infectious diseases,” Dr. Freda Lewis-Hall, executive vice president and chief medical officer of Pfizer Inc., said in a press release. “We continue to search for solutions to one of humanity’s most pressing challenges—defeating the microbes that cause infection and misery."
Zavicefta was developed in response to the medical need for new antibiotics for difficult-to-treat Gram-negative bacteria, many of which have become resistant to currently available antibiotics, according to the release.
The drug can be used to treat adults with complicated intra-abdominal infections, complicated urinary tract infections and hospital-acquired pneumonia, including ventilator-associated pneumonia.
Pfizer expects to have Zavicefta in additional markets outside the United States throughout this year and 2018, the release stated.
Pfizer's antibiotic drug Zavicefta available in Germany, United Kingdom
Organizations in this Story
Want to get notified whenever we write about Pfizer ?
Next time we write about Pfizer, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts